All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
What is new for treating acute GvHD?
Bookmark this article
During the 62nd ASH Annual Meeting and Exposition, the GvHD Hub was pleased to speak to Ali Bazarbachi, American University of Beirut, Beirut, LB, about the new advances for treating acute GvHD.
What is new for treating acute GvHD?
In this video, Bazarbachi discusses the results of a study evaluating the fecal microbiota transfer product MaaT013, a pooled-donor, full-ecosystem microbiota biotherapeutic, for the treatment of 29 patients with intestinal acute GvHD as part of a compassionate use/expanded access treatment program.
Your opinion matters
14 votes - 65 days left ...
Related articles
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox